# Veradermics' VDPHL01 Meets All Endpoints in Phase 3 Study '304' Part A

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/34839
Published: 2026-10-19T14:44:14.000Z
Updated: 2026-10-19T14:44:14.000Z
Section: Business

> The six-month, placebo-controlled portion of the trial enrolled 536 men with mild-to-moderate pattern hair loss.

Veradermics, Incorporated's lead candidate VDPHL01 met all primary and secondary endpoints in the six-month, placebo-controlled Part A of Phase 3 Study '304,' involving men with mild-to-moderate pattern hair loss.

Study '304' enrolled 536 men. Pattern hair loss is also known as androgenetic alopecia. The result covers Part A of the trial, which also includes a longer extension.

The finding gives Veradermics a positive late-stage result for its lead candidate. It applies to the six-month comparison with placebo, rather than the study's longer extension.